Literature DB >> 22719052

Resveratrol reduces steroidogenesis in rat ovarian theca-interstitial cells: the role of inhibition of Akt/PKB signaling pathway.

Israel Ortega1, Jesus A Villanueva, Donna H Wong, Amanda B Cress, Anna Sokalska, Scott D Stanley, Antoni J Duleba.   

Abstract

Polycystic ovary syndrome is characterized by theca-interstitial hyperplasia and increased expression of steroidogenic genes, leading to excessive androgen production. Resveratrol, a natural polyphenol, promotes apoptosis and reduces rat theca-interstitial cell growth, in part by inhibiting the mevalonate pathway and decreasing the availability of substrates of isoprenylation [farnesyl-pyrophosphate (FPP) and geranylgeranyl-pyrophosphate (GGPP)]. This study evaluated the effect of resveratrol on rat theca-interstitial cell steroidogenesis. Because resveratrol may activate sirtuins, this study also investigated whether steroidogenesis was affected by sirtuin inhibitors (nicotinamide, sirtinol). Theca-interstitial cells were cultured with or without resveratrol (1-10 μm), GGPP (30 μm), FPP (30 μm), nicotinamide (1 mm), and/or sirtinol (10 μm). Resveratrol did not affect progesterone levels but reduced androgen production in a concentration-dependent fashion (androstenedione by up to 78% and androsterone by up to 76%). This inhibitory effect correlated with a decrease in mRNA expression of genes regulating androgen production, especially Cyp17a1 (by up to 73%). GGPP and FPP had no effect on androgen levels and Cyp17a1 mRNA levels and did not alter the effects induced by resveratrol. Similarly, sirtuin inhibitors did not reverse resveratrol-induced inhibition of steroidogenesis. However, resveratrol decreased activity of serine-threonine kinase/protein kinase B pathway, a cell-signaling pathway involved in ovarian steroidogenesis. The present findings indicate that resveratrol reduces androgen production primarily by inhibiting Cyp17a1 mRNA expression, and this inhibition may be mediated, in part, by blocking the activity of the serine-threonine kinase/protein kinase B pathway. These findings may be of clinical relevance to conditions associated with excessive production of androgens by theca cells, such as polycystic ovary syndrome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22719052      PMCID: PMC3404354          DOI: 10.1210/en.2012-1385

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  46 in total

1.  Activation of the cAMP-dependent protein kinase signaling pathway by luteinizing hormone in trout theca layers.

Authors:  Eva Méndez; Mari Maeland; Bjørn S Skålhegg; Josep V Planas
Journal:  Mol Cell Endocrinol       Date:  2003-07-31       Impact factor: 4.102

Review 2.  The effects of the dietary polyphenol resveratrol on human healthy aging and lifespan.

Authors:  Agustín F Fernández; Mario F Fraga
Journal:  Epigenetics       Date:  2011-07-01       Impact factor: 4.528

3.  Simvastatin reduces steroidogenesis by inhibiting Cyp17a1 gene expression in rat ovarian theca-interstitial cells.

Authors:  Israel Ortega; Amanda B Cress; Donna H Wong; Jesus A Villanueva; Anna Sokalska; Ben C Moeller; Scott D Stanley; Antoni J Duleba
Journal:  Biol Reprod       Date:  2012-01-30       Impact factor: 4.285

4.  SIRT6 promotes DNA repair under stress by activating PARP1.

Authors:  Zhiyong Mao; Christopher Hine; Xiao Tian; Michael Van Meter; Matthew Au; Amita Vaidya; Andrei Seluanov; Vera Gorbunova
Journal:  Science       Date:  2011-06-17       Impact factor: 47.728

5.  A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

Authors:  E Diamanti-Kandarakis; C R Kouli; A T Bergiele; F A Filandra; T C Tsianateli; G G Spina; E D Zapanti; M I Bartzis
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

6.  Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells.

Authors:  J K Wickenheisser; P G Quinn; V L Nelson; R S Legro; J F Strauss; J M McAllister
Journal:  J Clin Endocrinol Metab       Date:  2000-06       Impact factor: 5.958

7.  Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro.

Authors:  Kaylon L Bruner-Tran; Kevin G Osteen; Hugh S Taylor; Anna Sokalska; Kaitlin Haines; Antoni J Duleba
Journal:  Biol Reprod       Date:  2010-09-15       Impact factor: 4.285

8.  Ontogeny of steroidogenic enzyme gene expression in ovarian theca-interstitial cells in the rat: regulation by a paracrine theca-differentiating factor prior to achieving luteinizing hormone responsiveness.

Authors:  T J Gelety; D A Magoffin
Journal:  Biol Reprod       Date:  1997-04       Impact factor: 4.285

9.  Phytoestrogen resveratrol suppresses steroidogenesis by rat adrenocortical cells by inhibiting cytochrome P450 c21-hydroxylase.

Authors:  V Supornsilchai; K Svechnikov; D Seidlova-Wuttke; W Wuttke; O Söder
Journal:  Horm Res       Date:  2005-11-01

10.  Luteinizing hormone-induced Akt phosphorylation and androgen production are modulated by MAP Kinase in bovine theca cells.

Authors:  Shin Fukuda; Makoto Orisaka; Kimihisa Tajima; Katsushige Hattori; Fumikazu Kotsuji
Journal:  J Ovarian Res       Date:  2009-11-16       Impact factor: 4.234

View more
  18 in total

1.  Resveratrol protects the ovary against chromium-toxicity by enhancing endogenous antioxidant enzymes and inhibiting metabolic clearance of estradiol.

Authors:  Sakhila K Banu; Jone A Stanley; Kirthiram K Sivakumar; Joe A Arosh; Robert C Burghardt
Journal:  Toxicol Appl Pharmacol       Date:  2016-04-27       Impact factor: 4.219

2.  Effects of Resveratrol on Receptor Expression and Serum Levels of Estrogen and Progesterone in the Rat Endometritis Model.

Authors:  Sevtap Han; Ali Fuat Cicek; Aytekin Tokmak; Tugce Yildirir Ustun; Nilufer Ercan Gokay; Mecit Orhan Uludag; Murside Ayse Demirel
Journal:  Reprod Sci       Date:  2021-05-08       Impact factor: 3.060

Review 3.  The Role and Application of Sirtuins and mTOR Signaling in the Control of Ovarian Functions.

Authors:  Alexander V Sirotkin
Journal:  Cells       Date:  2016-11-24       Impact factor: 6.600

4.  Resveratrol inhibits androgen production of human adrenocortical H295R cells by lowering CYP17 and CYP21 expression and activities.

Authors:  Nesa Marti; Nadia Bouchoucha; Kay-Sara Sauter; Christa E Flück
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

5.  Resveratrol supplementation rescues pool of growing follicles and ovarian stroma from Cisplatin-induced toxicity on the ovary in Sprague-Dawley rats: An experimental study.

Authors:  Gbotolorun Stella Chinwe; Okafor Izuchukwu Azuka; Ndoeche Chidinma Adaeze
Journal:  Int J Reprod Biomed       Date:  2018-01

6.  Resveratrol is not as effective as physical exercise for improving reproductive and metabolic functions in rats with dihydrotestosterone-induced polycystic ovary syndrome.

Authors:  Anna Benrick; Manuel Maliqueo; Sun Miao; Jesus A Villanueva; Yi Feng; Claes Ohlsson; Antoni J Duleba; Elisabet Stener-Victorin
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-08       Impact factor: 2.629

7.  Resveratrol potentiates effects of simvastatin on inhibition of rat ovarian theca-interstitial cells steroidogenesis.

Authors:  Israel Ortega; Jesus A Villanueva; Donna H Wong; Amanda B Cress; Anna Sokalska; Scott D Stanley; Antoni J Duleba
Journal:  J Ovarian Res       Date:  2014-02-13       Impact factor: 4.234

Review 8.  Complementary therapy in polycystic ovary syndrome.

Authors:  C I Aquino; S L Nori
Journal:  Transl Med UniSa       Date:  2014-04-24

Review 9.  MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease.

Authors:  Lina Schiffer; Punith Kempegowda; Wiebke Arlt; Michael W O'Reilly
Journal:  Eur J Endocrinol       Date:  2017-05-31       Impact factor: 6.664

Review 10.  New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome.

Authors:  Fatima Saleem; Syed W Rizvi
Journal:  Cureus       Date:  2017-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.